IMU Report

DailyReport

Snapshot

• Imugene Limited ASX: IMU
• Shares on issue: 4.3 billion
• Market Cap: 253 million
• Cash: 30 Million !!!
• Quarterly Spending: 3.6 million
• Recent Daily Volume: 51 Million

Company Highlights

• Develops ways to treat immune systems in cancer patients & eradicate tumours.
• It currently has a cancer vaccine which stimulates receptors in gastric & breast cancer called HER-Vaxx
• HER-Vaxx is in phase 1b/2 study for gastric cancer.
• Also developing PD1-Vaxx which is a cancer vaccine that aims to induce antibodies to treat tumours.
• Imugene Limited was incorporated in 1986 & HQ is in Sydney.

Comparison with others in the industry

Historic daily chart

21st August 2020 - ASXAnnouncement Review - Milestone

• Imugene has received the third ethics approval required to start the phase I human trial of their PD1-Vaxx [tumour reduction]
• Their site at Macquarie University has been activated & completed while patient screening has commenced there
• The clinical trials will include using 'non-small' cell lung cancer

18th August 2020 - ASXAnnouncement Review - Appendix 2A

• 17 million new shares issued @ 0.026

6th August 2020 - ASXAnnouncement - Clinical Guidance from US

• FDA gives guidance to IMU on process of the study including supporting the Phase 1 development plan
• Provides a US strategy in gaining Australian regulation

Disclaimer:
This is in no sense my recommendation to do anything to the stock only to create discussion and give information that i have sourced.